Evofem Biosciences Stock Revenue
| EVFMDelisted Stock | USD 0.05 0.0001 0.21% |
Evofem Biosciences fundamentals help investors to digest information that contributes to Evofem Biosciences' financial success or failures. It also enables traders to predict the movement of Evofem OTC Stock. The fundamental analysis module provides a way to measure Evofem Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Evofem Biosciences otc stock.
Evofem |
Evofem Biosciences OTC Stock Revenue Analysis
Evofem Biosciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Evofem Biosciences Revenue | 8.24 M |
Most of Evofem Biosciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Evofem Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Evofem Biosciences reported 8.24 M of revenue. This is 99.89% lower than that of the Pharmaceuticals sector and 98.89% lower than that of the Health Care industry. The revenue for all United States stocks is 99.91% higher than that of the company.
Evofem Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Evofem Biosciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Evofem Biosciences could also be used in its relative valuation, which is a method of valuing Evofem Biosciences by comparing valuation metrics of similar companies.Evofem Biosciences is currently under evaluation in revenue category among its peers.
Evofem Fundamentals
| Return On Equity | -3.87 | ||||
| Return On Asset | -1.25 | ||||
| Operating Margin | (5.41) % | ||||
| Current Valuation | 112.69 M | ||||
| Shares Outstanding | 121.22 M | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.57 % | ||||
| Number Of Shares Shorted | 8.68 M | ||||
| Price To Earning | (1.26) X | ||||
| Price To Book | 8.37 X | ||||
| Price To Sales | 0.42 X | ||||
| Revenue | 8.24 M | ||||
| Gross Profit | 4.19 M | ||||
| EBITDA | (204.14 M) | ||||
| Net Income | (205.19 M) | ||||
| Cash And Equivalents | 19.89 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 125.74 M | ||||
| Debt To Equity | 8.72 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | (0.77) X | ||||
| Cash Flow From Operations | (146.67 M) | ||||
| Short Ratio | 0.19 X | ||||
| Earnings Per Share | (19.01) X | ||||
| Target Price | 2.9 | ||||
| Number Of Employees | 119 | ||||
| Beta | -1.25 | ||||
| Market Capitalization | 6.41 M | ||||
| Total Asset | 42.51 M | ||||
| Retained Earnings | (526.68 M) | ||||
| Working Capital | 3.78 M | ||||
| Current Asset | 16.39 M | ||||
| Current Liabilities | 12.61 M | ||||
| Z Score | -30.0 | ||||
| Net Asset | 42.51 M |
About Evofem Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Evofem Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Evofem Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Evofem Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in census. Note that the Evofem Biosciences information on this page should be used as a complementary analysis to other Evofem Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Evofem OTC Stock
If you are still planning to invest in Evofem Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Evofem Biosciences' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |